Details for Patent: 10,548,846

Which drugs does patent 10,548,846 protect, and when does it expire?

Patent 10,548,846 protects BIKTARVY and is included in one NDA.

This patent has forty-one patent family members in twenty-nine countries.

Summary for Patent: 10,548,846

Patent landscape, scope, and claims:

Title:	Therapeutic compositions for treatment of human immunodeficiency virus
Abstract:	A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
Inventor(s):	Collman; Benjamin Micah (Foster City, CA), Hong; Lei (Cupertino, CA), Koziara; Joanna M. (Foster City, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	15/346,335
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,548,846
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 10,548,846

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes	10,548,846		Y

International Family Members for US Patent 10,548,846

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	106645
Australia	2016354007
Australia	2020200995
Brazil	102016026127